Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Aug 13, 2021 12:46pm
119 Views
Post# 33701167

RE:RE:RE:RE:Whats this?

RE:RE:RE:RE:Whats this?I started to read the article, but just at the chemistry section I was baffled. First they finally give the amino acids sequence of TH19P01 which is:

Acetyl-Gly-Val-Arg-Ala-Lys-Ala-Gly-Val-Arg-Asn-(Nle)-Phe-Lys-Ser-Glu-Ser-Tyr

So they have two lysines (Lys) strategically situated on both side of the peptide, with a nice gap in the middle. It's on these two lysines that the linker + docetaxel will be achored to the peptide. They have an acetyl group on the N-terminus of the peptide to give it more stability against enzymatic cleavage, they also have a norleucine (Nle) in the middle, which is probably a more stable (non sulfur) replacement for methionine.

That being said what I don't understand in the chemistry part is the linker. They use succinic anhydride to attach docetaxel to the lysines on the peptide, leaving a linker structure that is not what I saw in one of their previous presentation where they were claiming to use dimethyl glutaryl linker. And in the article, after descrbing the chemical reactions they end up with a molecule called TH19P01(SuDoce)2 or TH1902. So they claim there that the PDC with the succinyl linker is TH1902. It does not make sense because the succinyl linker is not cleavable under physilogic conditions. It is categorized as a non cleavable linker for ADCs. So I really don't understand why they claim that TH1902 has a succinyl linker, while before, they claimed it was dimethyl glutaryl.

https://www.selleckchem.com/products/succinic-anhydride.html


<< Previous
Bullboard Posts
Next >>